Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common stock, par value $0.00001
-
Shares outstanding
-
43,754,363
-
Total 13F shares
-
5,096,844
-
Share change
-
-8,895,325
-
Total reported value
-
$1,528,840
-
Put/Call ratio
-
28%
-
Price per share
-
$0.30
-
Number of holders
-
30
-
Value change
-
-$20,664,144
-
Number of buys
-
15
-
Number of sells
-
15
Institutional Holders of Cellectar Biosciences, Inc. - Common stock, par value $0.00001 (CLRB) as of Q4 2024
As of 31 Dec 2024,
Cellectar Biosciences, Inc. - Common stock, par value $0.00001 (CLRB) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,096,844 shares.
The largest 10 holders included
VANGUARD GROUP INC, ADAR1 Capital Management, LLC, Squarepoint Ops LLC, UBS Group AG, GEODE CAPITAL MANAGEMENT, LLC, BlackRock, Inc., Altium Capital Management LLC, BANK OF AMERICA CORP /DE/, JPMORGAN CHASE & CO, and MORGAN STANLEY.
This page lists
30
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.